Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrolapitant and Palonosetron for CINV in Esophageal and Lung Cancer
NCT07617246Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of fosrolapitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Nov 2025; status: recruiting.
02
Drugs
fosrolapitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07617246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617246.